The search for CJC-1295 in Kisai almost always leads to the same conclusion: research peptides are delivered through specialist online vendors, not brick-and-mortar outlets. The practical advantage of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers better verification tools than any physical store could provide. Separating genuine research-grade CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram documenting ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Kisai researchers need to know about purchasing, testing, and working with CJC-1295 for scientific research use.
CJC-1295 Mechanisms Explained
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Kisai researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Buying CJC-1295: Quality Markers to Look For
Evaluating CJC-1295 vendors starts with the COA: access the batch-specific certificate before placing an order, not after. The HPLC chromatogram is the most important document in the COA: it should show a clear dominant peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be stated as ≥98%. Negative indicators in CJC-1295 vendor evaluation: prices significantly below market average, no information about manufacturing source, no community presence, and COAs that lack endotoxin data. Price is an ineffective primary criterion for CJC-1295 quality — research-grade synthesis and testing has genuine production costs that cannot be cut without consequences, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Kisai
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the comprehensive clinical trial data that characterises approved medications. Proper handling of CJC-1295 requires strict sterile technique during reconstitution — alcohol-swabbed septum, fresh needles, clean working environment — and cold chain maintenance from receipt through use. Bacterial endotoxin contamination is the most serious safety risk specific to research peptides — verify endotoxin testing is documented in your batch COA before any injectable research application. The research literature on CJC-1295 should be read critically before planning any study — study designs, dosing ranges, and outcome measures vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
